Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.0350+0.3750 (+14.10%)
As of 10:55AM EDT. Market open.
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
48,503
130
84,683
10,650
7,756
Operating expenses
Research development
173,982
182,945
159,188
138,693
182,243
Selling general and administrative
80,164
66,983
117,307
89,057
46,881
Total operating expenses
250,787
247,138
271,741
225,426
219,693
Operating income or loss
-202,284
-247,008
-187,058
-214,776
-211,937
Total other income/expenses net
-7,637
-11,077
-3,113
-36,608
1,526
Income before tax
-190,099
-234,632
-183,118
-250,219
-204,472
Income from continuing operations
-190,099
-234,632
-183,118
-250,219
-204,472
Net income
-190,099
-234,632
-183,118
-250,219
-204,472
Net income available to common shareholders
-190,099
-234,632
-183,118
-250,219
-208,054
Basic EPS
-0.76
-
-0.74
-1.84
-0.98
Diluted EPS
-0.76
-
-0.74
-1.84
-0.98
Basic average shares
250,149
-
247,080
135,918
211,746
Diluted average shares
250,149
-
247,080
135,918
211,746